Margarita Maurer

Margarita Maurer

UNVERIFIED PROFILE

Are you Margarita Maurer?   Register this Author

Register author
Margarita Maurer

Margarita Maurer

Publications by authors named "Margarita Maurer"

Are you Margarita Maurer?   Register this Author

23Publications

366Reads

45Profile Views

Signal Sequence Receptor 2 is required for survival of human melanoma cells as part of an unfolded protein response to endoplasmic reticulum stress.

Mutagenesis 2016 09 14;31(5):573-82. Epub 2016 May 14.

Division of Immunology Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna A-1090, Austria,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/mutage/gew023DOI Listing
September 2016

Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome.

Hum Pathol 2016 08 21;54:157-64. Epub 2016 Apr 21.

Division of Immunology Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Vienna, Austria, A-1090. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2016.03.022DOI Listing
August 2016

Comprehensive comparative and semiquantitative proteome of a very low number of native and matched epstein-barr-virus-transformed B lymphocytes infiltrating human melanoma.

J Proteome Res 2014 Jun 6;13(6):2830-45. Epub 2014 May 6.

Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University of Vienna , Waehringer Guertel 18-20, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/pr401270yDOI Listing
June 2014

Combining filter-aided sample preparation and pseudoshotgun technology to profile the proteome of a low number of early passage human melanoma cells.

J Proteome Res 2013 Feb 24;12(2):1040-8. Epub 2012 Dec 24.

Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/pr301009uDOI Listing
February 2013

PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.

Biochem Pharmacol 2012 Nov 14;84(10):1318-31. Epub 2012 Aug 14.

Cell Cycle Regulation Group, Dept. of Medicine I, Div.: Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2012.07.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494830PMC
November 2012

Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches.

Oncoimmunology 2012 Nov;1(8):1454-1456

Division of Immunology, Allergy and Infectious Diseases; Department of Dermatology; Vienna, Austria.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/onci.21357
Publisher Site
http://dx.doi.org/10.4161/onci.21357DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518536PMC
November 2012

Promotion of apoptosis in cancer cells by selective purine-derived pharmacological CDK inhibitors: one outcome, many mechanisms.

Curr Pharm Des 2011 ;17(3):256-71

Cell Cycle Regulation Group, Department of Medicine Div.: Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138161211795049714DOI Listing
September 2011

Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.

J Cell Biochem 2011 Apr;112(4):1103-17

Cell Cycle Regulation Group, Institute of Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.23024DOI Listing
April 2011

Triazoloacridone C-1305 abrogates the restriction checkpoint in cells lacking functional p53 and promotes their accumulation in the G2/M phase of the cell cycle.

J Exp Ther Oncol 2011 ;9(1):5-15

Cell Cycle Regulation Group, Institute of Cancer Research, Dept. of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
March 2011

Effect of anti-estrogen combined with roscovitine, a selective CDK inhibitor, on human breast cancer cells differing in expression of ER.

J Exp Ther Oncol 2011 ;9(1):17-25

Cell Cycle Regulation Group, Division, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
March 2011

Roscovitine, a small molecule CDK inhibitor induces apoptosis in multidrug-resistant human multiple myeloma cells.

J Exp Ther Oncol 2011 ;9(1):27-35

Cell Cycle Regulation Group, Division, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
March 2011

Tamoxifen enhances the anti-proliferative effect of roscovitine, a selective cyclin-dependent kinase inhibitor, on human ER-positive human breast cancer cells.

J Exp Ther Oncol 2011 ;9(1):37-45

Cell Cycle Regulation Group, Div., Institute of Cancer Research, Dept. of Medicine I, Medical University of Vienna, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
March 2011

Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.

J Cell Biochem 2011 Mar;112(3):761-72

Cell Cycle Regulation Group, Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.23004DOI Listing
March 2011

Whether to target single or multiple CDKs for therapy? That is the question.

J Cell Physiol 2011 Feb;226(2):341-9

Cell Cycle Regulation Group, Div., Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.22426DOI Listing
February 2011

Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors.

J Cell Biochem 2011 Jan;112(1):273-88

Dept. of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.22918DOI Listing
January 2011

Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential.

Acta Biochim Pol 2009 31;56(3):495-501. Epub 2009 Aug 31.

Cell Cycle Regulation Group, Department of Medicine I, Division: Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, Vienna, Austria.

View Article

Download full-text PDF

Source
January 2010

Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells.

Ann N Y Acad Sci 2009 Aug;1171:250-6

Department of Medicine I, Div Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1749-6632.2009.04717.xDOI Listing
August 2009

Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment.

J Cell Biochem 2009 Apr;106(5):937-55

Cell Cycle Regulation Group, Department of Medicine I, Div. Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.22074DOI Listing
April 2009

Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells.

Food Chem Toxicol 2008 Apr 11;46(4):1327-33. Epub 2007 Sep 11.

Cell Cycle Regulation Group, Department of Medicine I, Division: Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8 a, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.fct.2007.09.004DOI Listing
April 2008

Inhibition of farnesyl protein transferase sensitizes human MCF-7 breast cancer cells to roscovitine-mediated cell cycle arrest.

J Cell Biochem 2007 Oct;102(3):736-47

Department of Medicine I, Div.: Institute of Cancer Research, Vienna Medical University, Vienna, Austria.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jcb.21325
Publisher Site
http://dx.doi.org/10.1002/jcb.21325DOI Listing
October 2007

Phenol red in the culture medium strongly affects the susceptibility of human MCF-7 cells to roscovitine.

Cell Mol Biol Lett 2007 19;12(2):280-93. Epub 2007 Jan 19.

Institute of Cancer Research, Department of Medicine I, Vienna Medical University, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2478/s11658-007-0002-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276014PMC
August 2007

Cellular and organismal ageing: Role of the p53 tumor suppressor protein in the induction of transient and terminal senescence.

J Cell Biochem 2007 Aug;101(6):1355-69

Cell Cycle Regulation Group, Department of Medicine I, Division: Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.21383DOI Listing
August 2007